Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances (‘legal highs’) in New Zealand-Reference-Cited by-同舟云学术

Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances (‘legal highs’) in New Zealand

Published:2017-02-23 Issue:5 Volume:36 Page:589-596
ISSN:0959-5236
Container-title:Drug and Alcohol Review
language:en
Short-container-title:Drug Alcohol Rev.

Author:

Rychert Marta¹,Wilkins Chris¹,Witten Karen¹

Affiliation:

1. SHORE & Whariki Research Centre; Massey University; Auckland New Zealand

Publisher

Wiley

Subject

Health (social science),Medicine (miscellaneous)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dar.12507/fullpdf

Reference41 articles.

1. New Zealand Parliament Psychoactive Substances Act 2013. Public Act No 53 2013 http://www.legislation.govt.nz/act/public/2013/0053/20.0/DLM5042921.html http://www.webcitation.org/6aiNkjonQ

2. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand;Wilkins;Addiction,2014

3. The new drug phenomenon;Brandt;Drug Test Anal,2014

4. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?;Bretteville-Jensen;Addiction,2014

5. Drug policy and global regulatory capitalism: the case of new psychoactive substances (NPS);Seddon;Int J Drug Policy,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic cathinones;Novel Psychoactive Substances;2022

2. Commentary on Rychert and Wilkins (2021) ‘Why did New Zealand's referendum to legalise recreational cannabis fail?’;Drug and Alcohol Review;2021-05-18

3. Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre;Clinical Toxicology;2020-11-06

4. Current cannabis-related situation in the Asia-Pacific region;Current Opinion in Psychiatry;2020-06-08

5. How deaths can help clinicians and policy‐makers understand the risks of novel psychoactive substances;British Journal of Clinical Pharmacology;2020-01-14